Epigenetic therapies to differentiate and eradicate leukaemia stem cells

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1146192

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Leukemia stem cells (LSC) are often resistant to conventional and targeted therapies and therefore serve as the seed for leukaemia relapse. The overall aim of this project is to use small molecule therapies to block the activity of a particular protein (LSD1) in LSC in order to differentiate them and expose a vulnerability to another epigenetic therapy called a BET inhibitor. Together, these epigenetic therapies will differentiate and eradicate LSC, leading to improved outcome in AML.

Funded Activity Details

Start Date: 01-01-2019

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $674,315.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biochemistry | bioinformatics | epigenetics | leukaemia | molecular biology

Related Links